Skip to main content
SRPT
NASDAQ Life Sciences

Sarepta Therapeutics CEO Douglas Ingram Announces Retirement by End of 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$18.35
Mkt Cap
$1.988B
52W Low
$10.415
52W High
$109.55
52W Position info
76% above low
Off High info
83% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SRPT sits 76% above its 52-week low of $10.415.

Summary

Sarepta Therapeutics announced that CEO Douglas Ingram plans to retire by the end of 2026, initiating a search for his successor.


Key Events · Executive and Board Changes · SRPT

  • CEO Retirement Announced

    Douglas Ingram notified Sarepta Therapeutics, Inc. of his decision to retire as Chief Executive Officer.

  • Planned Transition Timeline

    Mr. Ingram's retirement is planned for the end of 2026 or upon the appointment of his replacement, indicating an orderly transition.

  • Successor Search Initiated

    The company has commenced a search for both internal and external candidates to find Mr. Ingram's successor.


Analysis · SRPT · Life Sciences

The planned retirement of CEO Douglas Ingram introduces a period of leadership transition for Sarepta Therapeutics. While the announcement specifies an orderly departure by the end of 2026 or upon the appointment of a successor, the change in top leadership can create uncertainty regarding future strategic direction and operational execution. The company has initiated a search for both internal and external candidates, which will be a key focus for investors in the coming months.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRPT was trading at $18.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.42 to $109.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.93
Real-time Price: $13.64 info
Change: -$4.30 (-24%) info
Market Cap: $1.456B info
SRPT
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.65
Real-time Price: $13.64 info
Change: -$3.01 (-18%) info
Market Cap: $1.456B info
SRPT
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.57
Real-time Price: $13.64 info
Change: -$3.94 (-22%) info
Market Cap: $1.456B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.64 info
Change: -$5.01 (-27%) info
Market Cap: $1.456B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.64 info
Change: -$5.40 (-28%) info
Market Cap: $1.456B info